Intellia Reports Q4 2025 Financial Results

Intellia Therapeutics on February 26 announced fiscal Q4 and full-year 2025 results, reporting $605.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025, down from $861.7 million a year earlier. Management said the cash runway extends into the second half of 2027 and through lonvo‑z’s anticipated U.S. commercial launch for HAE, while collaboration revenue rose to $23.0 million from $12.9 million.